局部晚期或转移性儿童及青少年分化型甲状腺癌的基因特征与临床特征及131I疗效的关系

doi:10.19401/j.cnki.1007-3639.2022.05.002

摘要/Abstract

摘要：

背景与目的： 儿童及青少年分化型甲状腺癌（differentiated thyroid cancer,DTC）的分子生物学特征及其临床指导意义尚不明确。本研究拟初步探讨局部晚期或转移性DTC患儿的基因特征分布及其与临床特征及¹³¹I疗效的关系。方法： 采用甲状腺癌相关基因panel（ThyroLead^®）对2020年12月—2021年7月就诊于中国医学科学院北京协和医学院北京协和医院的儿童及青少年侵袭性DTC的原发灶进行测序,并回顾性收集患儿的临床病理学特征及¹³¹I治疗相关资料,分析其基因特征与其临床病理学特征及¹³¹I疗效的关系。结果： 本队列纳入39例局部晚期或转移性患儿,可及数据中所有患儿均存在淋巴结转移,侧方区受累率达91.4%（32/35）,远处转移率达61.5%（24/39）。61.5%（24/39）的患儿检出甲状腺癌相关基因变异,其中以RET融合（38.5%,15/39）和BRAF V600E点突变（12.8%,5/39）最为常见。突变组与非突变组的临床特征差异无统计学意义（P>0.05）。远处转移中,91.7%（22/24）的患儿在¹³¹I治疗后仍呈结构性疗效不佳（structural incomplete response,SIR）状态,其中9例患儿呈放射性碘难治（radioactive iodine-refractory,RAIR）状态。RAIR状态患儿中88.9%（8/9）检出相关基因变异,其中NCOA4/RET融合占62.5%（5/8）。进一步将RET变异组患儿细化分组显示,与其他形式的RET融合相比,NCOA4/RET融合阳性者远处转移率更高（33.3% vs 88.9%,P=0.089）,提示其具有更高的远处侵犯倾向。结论： 局部晚期或转移性DTC患儿的基因突变以融合突变尤其是RET融合为主,其中NCOA4/RET融合阳性者似乎显示出更强的侵袭性,更易呈RAIR状态。

关键词: 儿童及青少年甲状腺癌, 局部晚期, 远处转移, 基因变异, RET融合, 放射性碘难治

Abstract:

Background and purpose: The molecular characteristics of differentiated thyroid cancer (DTC) in children and adolescents and its role in clinical practice remain unclear. This study intended to explore the genetic characteristics and its relationship with clinical characteristics and efficacy of ¹³¹I therapy in locally advanced or metastatic pediatric and adolescent DTC patients. Methods: A thyroid cancer-related gene panel (ThyroLead®) was used to test the primary tumors from children and adolescents with DTC treated in Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College from December 2020 to July 2021. The samples were sequenced, the clinicopathological characteristics and ¹³¹I treatment history were retrospectively collected, and the relationship between their genetic characteristics and clinicopathological characteristics and the efficacy of ¹³¹I therapy was analyzed. Results: All the 39 children present locally advanced or metastatic disease. All the children with accessible data had lymph node metastasis, 91.4% (32/35) of whom had lateral lymph node metastasis, and 61.5% (24/39) patients had distant metastasis. Thyroid cancer-related gene variants were detected in 61.5% (24/39) of the patients, among which RET fusion (38.5%, 15/39) and BRAF V600E point mutation (12.8%, 5/39) were the most common. No statistically significant differences were found in clinical characteristics between the mutation group and the non-mutation group (P>0.05). Most of the children (91.7%, 22/24) with distant metastases remained structural incomplete response (SIR) status after ¹³¹I treatment. Nine patients were considered radioactive iodine-refractory (RAIR) status, and 8 of them had thyroid cancer driver mutations, among which NCOA4/RET accounted for 62.5% (5/8). Among cases with RET genetic variations, NCOA4/RET fusion-positive patients tended to present more distant metastasis than those with other forms of RET fusion (33.3% vs 88.9%, P=0.089). Conclusion: Compared with point mutations, fusion gene mutations, especially RET fusions, are more common in locally advanced or metastatic pediatric and adolescent DTC patients. NCOA4/RET fusion-positive tumor has more aggressive behaviors and are more likely to become RAIR.

Key words: Pediatric and adolescent thyroid cancer, Locally advanced, Metastases, Genetic alterations, RET fusions, Radioactive iodine-refractory

中图分类号:

R736.1

孙迪, 孙郁青, 张鑫, 黄丽莎, 林岩松. 局部晚期或转移性儿童及青少年分化型甲状腺癌的基因特征与临床特征及¹³¹I疗效的关系[J]. 中国癌症杂志, 2022, 32(5): 380-387.

SUN Di, SUN Yuqing, ZHANG Xin, HUANG Lisha, LIN Yansong. The relationship between genetic characteristics and clinical characteristics and the efficacy of ¹³¹I therapy in children and adolescents with locally advanced or metastatic differentiated thyroid cancer[J]. China Oncology, 2022, 32(5): 380-387.

图/表 4

表1

图1

表2

图2

参考文献 28

[1]	WARD E, DESANTIS C, ROBBINS A, et al. Childhood and adolescent cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(2): 83-103. doi: 10.3322/caac.21219
[2]	MILLER K D, FIDLER-BENAOUDIA M, KEEGAN T H, et al. Cancer statistics for adolescents and young adults, 2020[J]. CA Cancer J Clin, 2020, 70(6): 443-459. doi: 10.3322/caac.21637
[3]	BERNIER M O, WITHROW D R, BERRINGTON DE GONZALEZ A, et al. Trends in pediatric thyroid cancer incidence in the United States, 1998-2013[J]. Cancer, 2019, 125(14): 2497-2505. doi: 10.1002/cncr.32125
[4]	HAY I D, GONZALEZ-LOSADA T, REINALDA M S, et al. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008[J]. World J Surg, 2010, 34(6): 1192-1202. doi: 10.1007/s00268-009-0364-0
[5]	ALZAHRANI A S, MURUGAN A K, QASEM E, et al. Single point mutations in pediatric differentiated thyroid cancer[J]. Thyroid, 2017, 27(2): 189-196. doi: 10.1089/thy.2016.0339
[6]	HAY I D, JOHNSON T R, KAGGAL S, et al. Papillary thyroid carcinoma (PTC) in children and adults: comparison of initial presentation and long-term postoperative outcome in 4 432 patients consecutively treated at the mayo clinic during eight decades (1936-2015)[J]. World J Surg, 2018, 42(2): 329-342. doi: 10.1007/s00268-017-4279-x
[7]	PAWELCZAK M, DAVID R, FRANKLIN B, et al. Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases following ¹³¹I treatment: a systematic review[J]. Thyroid, 2010, 20(10): 1095-1101. doi: 10.1089/thy.2009.0446
[8]	ALZAHRANI A S, ALSWAILEM M, MORIA Y, et al. Lung metastasis in pediatric thyroid cancer: radiological pattern, molecular genetics, response to therapy, and outcome[J]. J Clin Endocrinol Metab, 2019, 104(1): 103-110. doi: 10.1210/jc.2018-01690
[9]	BIKO J, REINERS C, KREISSL M C, et al. Favourable course of disease after incomplete remission on (131)I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up[J]. Eur J Nucl Med Mol Imaging, 2011, 38(4): 651-655. doi: 10.1007/s00259-010-1669-9
[10]	CORDIOLI M I, MORAES L, CURY A N, et al. Are we really at the dawn of understanding sporadic pediatric thyroid carcinoma?[J]. Endocr Relat Cancer, 2015, 22(6): R311-R324. doi: 10.1530/ERC-15-0381
[11]	ALZAHRANI A S, QASEM E, MURUGAN A K, et al. Uncommon TERT promoter mutations in pediatric thyroid cancer[J]. Thyroid, 2016, 26(2): 235-241. doi: 10.1089/thy.2015.0510
[12]	ALZAHRANI A S, ALSWAILEM M, ALSWAILEM A A, et al. Genetic alterations in pediatric thyroid cancer using a comprehensive childhood cancer gene panel[J]. J Clin Endocrinol Metab, 2020, 105(10): 3324-3334. doi: 10.1210/clinem/dgaa389
[13]	GUO K, QIAN K, SHI Y, et al. Clinical and molecular characterizations of papillary thyroid cancer in children and young adults: a multicenter retrospective study[J]. Thyroid, 2021, 31(11): 1693-1706. doi: 10.1089/thy.2021.0003
[14]	AMIN M B, EDGE S B, GREENE F L, et al. AJCC cancer staging manual[M]. 8th ed. New York: Springer, 2017.
[15]	HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133. doi: 10.1089/thy.2015.0020
[16]	GALUPPINI F, VIANELLO F, CENSI S, et al. Differentiated thyroid carcinoma in pediatric age: genetic and clinical scenario[J]. Front Endocrinol (Lausanne), 2019, 10: 552. doi: 10.3389/fendo.2019.00552
[17]	FRANCIS G L, WAGUESPACK S G, BAUER A J, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2015, 25(7): 716-759. doi: 10.1089/thy.2014.0460
[18]	SATAPATHY S, BAL C. Genomic landscape of sporadic pediatric differentiated thyroid cancers: a systematic review and meta-analysis[J]. J Pediatr Endocrinol Metab, 2022. Online ahead of print.
[19]	RANGEL-POZZO A, SISDELLI L, CORDIOLI M I V, et al. Genetic landscape of papillary thyroid carcinoma and nuclear architecture: an overview comparing pediatric and adult populations[J]. Cancers, 2020, 12(11): 3146. doi: 10.3390/cancers12113146
[20]	NIKIFOROV Y E, ROWLAND J M, BOVE K E, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children[J]. Cancer Res, 1997, 57(9): 1690-1694.
[21]	GERTZ R J, NIKIFOROV Y, REHRAUER W, et al. Mutation in BRAF and other members of the MAPK pathway in papillary thyroid carcinoma in the pediatric population[J]. Arch Pathol Lab Med, 2016, 140(2): 134-139. doi: 10.5858/arpa.2014-0612-OA
[22]	FRANCO A T, RICARTE-FILHO J C, LAETSCH T W, et al. Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer[J]. J Clin Invest, 2021, 131(18): e152696. doi: 10.1172/JCI152696
[23]	PEKOVA B, SYKOROVA V, DVORAKOVA S, et al. RET, NTRK, ALK, BRAF and MET fusions in a large cohort of pediatric papillary thyroid carcinomas[J]. Thyroid, 2020, 30(12): 1771-1780. doi: 10.1089/thy.2019.0802
[24]	OISHI N, KONDO T, NAKAZAWA T, et al. Frequent BRAF V600E and absence of TERT promoter mutations characterize sporadic pediatric papillary thyroid carcinomas in Japan[J]. Endocr Pathol, 2017, 28(2): 103-111. doi: 10.1007/s12022-017-9470-y
[25]	NIKIFOROV Y E, NIKIFOROVA M N, GNEPP D R, et al. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident[J]. Oncogene, 1996, 13(4): 687-693.
[26]	SMIDA J, ZITZELSBERGER H, KELLERER A M, et al. p53 mutations in childhood thyroid tumours from Belarus and in thyroid tumours without radiation history[J]. Int J Cancer, 1997, 73(6): 802-807. doi: 10.1002/(SICI)1097-0215(19971210)73:6<802::AID-IJC5>3.0.CO;2-6
[27]	MALAGUARNERA R, VELLA V, VIGNERI R, et al. p53 family proteins in thyroid cancer[J]. Endocr Relat Cancer, 2007, 14(1): 43-60. doi: 10.1677/erc.1.01223
[28]	MARTI J L, JAIN K S, MORRIS L G T. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer[J]. Thyroid, 2015, 25(6): 681-687. doi: 10.1089/thy.2015.0067

Clinical characteristic	All patients	Mutation negative	Mutation positive	P value	U value
Age at diagnosis/year median (IQR)	12.1 (9.1-16.2)	11.9 (7.3-14.1)	13.1 (10.0-16.8)	0.172	228.000
Adolescence or not				0.323^*
Children	21	10	11
Adolescent	18	5	13
Gender				0.742^*
Male	18	6	12
Female	21	9	12
Number of surgery median (IQR)	2 (1-2)	1 (1-2)	2 (1-2)	0.618	198.000
Tumor size D/cm median (IQR)	2.7 (1.5-3.9)	3.0 (1.4-3.5)	2.5 (1.5-4.0)	0.558	130.500
Histology				1.000^*
PTC	38	15	23
FTC	1	0	1
T stage				0.471	145.500
T₁+T₂	16	7	9
T₃+T₄	17	5	12
NA	6	3	3
N stage				0.601	158.500
N_1a	3	2	1
N_1b	32	11	21
NA	4	2	2
M stage				1.000^*
M₀	15	6	9
M₁	24	9	15
Number of RAI therapy median (IQR)	2 (1-2)	1 (1-3)	2 (1-2)	0.943	177.500
Cumulative RAI dose D/mCi median (IQR)	180 (125-300)	160 (70-225)	260 (150-300)	0.202	207.000
RAIR or not				0.228^*
No	30	11	19
Yes	9	1	8
Follow-up period t/month median (IQR)	40.0 (21.0-57.0)	36.0 (21.0-72.0)	41.5 (23.0-56.8)	0.700	193.500
ATA response classification at last follow-up				0.853	186.500
ER	5	2	3
IDR	8	3	5
BIR	4	2	2
SIR	22	8	14

No.	Age at diagnosis/year	Gender	Number of surgery	Tumor size D/cm	Histology (subtype)	T stage	N stage	M stage (site)	Number of RAI therapy	Cumulative RAI dose D/mCi	Follow-up period t/month	Classification of RAIR	Genetic variation
1	16.0	Male	2	4	PTC (classic)	3b	1b	1 (lung)	2	270	51	4^*	NCOA4/RET fusion
2	7.0	Male	1	2.8	PTC (follicular)	3b	1b	1 (lung)	2	250	57	4^*	TP53 R213E mutation, NCOA4/RET fusion
3	13.2	Female	1	4.0	PTC (NA)	2	1b	1 (lung)	3	425	43	4^*	NCOA4/RET fusion
4	14.8	Male	2	3.5	PTC (classic)	2	1b	1 (lung)	2	300	52	4^*	NCOA4/RET fusion
5	11.9	Female	3	2.5	PTC (NA)	4a	1b	1 (lung）	2	270	45	2^#	NCOA4/RET fusion
6	8.9	Male	2	2.5	PTC (DSV)	2	1b	1 (lung)	5	280	78	4^*	CCDC6/RET fusion
7	9.1	Female	1	1.5	PTC (classic)	3b	1b	1 (lung)	2	165	40	1^△	TFG/NTRK1 fusion
8	16.8	Male	3	4.5	PTC (classic)	4b	1b	1 (lung & bone)	2	180	134	1^△	BRAF V600E mutation
9	11.2	Female	2	1.4	PTC (NA)	1b	1b	1 (lung)	3	315	106	1^△	negative

局部晚期或转移性儿童及青少年分化型甲状腺癌的基因特征与临床特征及¹³¹I疗效的关系

The relationship between genetic characteristics and clinical characteristics and the efficacy of ¹³¹I therapy in children and adolescents with locally advanced or metastatic differentiated thyroid cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	江健韵, 翟瑞萍, 应红梅. 身体剂量参数对局部晚期鼻咽癌患者免疫细胞减少的影响分析：一项回顾性队列研究[J]. 中国癌症杂志, 2023, 33(10): 898-907.
[2]	庄晗, 凌池芳, 王佳舟, 韩序, 姜睿, 胡伟刚. 局部晚期胰腺癌75 Gy同步加量放射治疗的剂量可行性研究[J]. 中国癌症杂志, 2023, 33(1): 54-60.
[3]	许婷婷, 胡超苏, 李宝生. 抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）[J]. 中国癌症杂志, 2023, 33(1): 81-94.
[4]	邓姝婷, 冯源, 钱凯, 郭凯, 王卓颖. 基因突变特征与儿童及青少年分化型甲状腺癌远处转移相关性的meta分析[J]. 中国癌症杂志, 2022, 32(5): 388-396.
[5]	马光, 区晓敏, 胡超苏, 宋少莉, 杨忠毅. 治疗前¹⁸F-FLT和¹⁸F-FDG PET/CT摄取异质性在局部晚期鼻咽癌疗效预测中的价值[J]. 中国癌症杂志, 2022, 32(4): 309-315.
[6]	卢大松, 冯勇军, 王武峰, 牟忠林, 赵　娜. 个体化营养干预对局部晚期鼻咽癌患者生活质量及生存预后的影响[J]. 中国癌症杂志, 2021, 31(12): 1202-1208.
[7]	张晓萌 , 麻宁一 , 祝鸿程 , 艾沓杉 , 任志刚 . 胰腺癌术后辅助性放化疗的效果及预后因素分析[J]. 中国癌症杂志, 2020, 30(7): 519-524.
[8]	沈　洁, 莫　淼, 袁　晶, 周昌明, 王泽洲, 张志红, 温　灏, 吴小华, 郑　莹 . 1 313例局部晚期宫颈癌患者的长期生存报告：以医院为基础的真实世界研究[J]. 中国癌症杂志, 2020, 30(3): 192-198.
[9]	眭慧敏，刘杰蕊，王瞳，朱朝晖，林岩松. 儿童及青少年分化型甲状腺癌远处转移的临床病理学危险因素分析[J]. 中国癌症杂志, 2019, 29(6): 423-428.
[10]	高璐滢，林岩松，姜玉新，李建初，李慧，张波，刘如玉，席雪华，高琼，王莹，赵瑞娜. 颈部超声联合血清甲状腺球蛋白评估阿帕替尼治疗进展性碘难治性分化型甲状腺癌的短期疗效[J]. 中国癌症杂志, 2019, 29(6): 418-422.
[11]	郑营营,徐俊彦,张建平,等. ¹⁸F-FDG PET/CT纹理分析预测局部晚期直肠癌新辅助放化疗疗效的价值[J]. 中国癌症杂志, 2018, 28(8): 590-594.
[12]	徐　晔,周　洋,唐　娜,等. 中段直肠癌术前磁共振成像对术后复发及转移的预测价值研究[J]. 中国癌症杂志, 2018, 28(5): 376-382.
[13]	刘晓文,龙子雯,蔡　宏,等. 局部进展期胃癌术前化疗与术前放化疗的对比研究[J]. 中国癌症杂志, 2018, 28(10): 762-768.
[14]	张　琴, 傅小龙,蔡旭伟,等. 手术完全切除的Ⅲ_A(N₂)期非小细胞肺癌失败表型分析[J]. 中国癌症杂志, 2017, 27(5): 383-388.
[15]	马若翔,李永国,朱　英,等. 肺癌组织中STR基因座变异规律的研究[J]. 中国癌症杂志, 2017, 27(5): 353-358.